The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival

Saved in:
Bibliographic Details
Published in:Haematologica (Roma) 2024-10, Vol.109 (10), p.3379-3382
Main Authors: Danilov, Alexey V, Flinn, Ian W, Davids, Matthew S, Gregory, Beth, Bentur, Ohad, Sidransky, David, Brown, Jennifer R
Format: Article
Language:English
Subjects:
Aged
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - therapeutic use
Female
Humans
Isoquinolines - administration & dosage
Isoquinolines - therapeutic use
Letter to the Editor
Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell - mortality
Male
Middle Aged
Phosphoinositide-3 Kinase Inhibitors - therapeutic use
Purines - therapeutic use
Recurrence
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0390-6078
1592-8721
1592-8721
DOI:10.3324/haematol.2024.285043